Navigation Links
Concurrent chemo and radiation confers survival benefit in nasopharyngeal carcinoma patients
Date:11/4/2011

The combination of chemotherapy and radiation significantly improved the 5-year overall survival of patients with stage II nasopharyngeal carcinoma (NPC), according to a phase III study published Nov. 4 in the Journal of the National Cancer Institute.

Nasopharyngeal carcinoma is endemic in Southern China and Southeast Asia, where radiotherapy (RT) has been the primary treatment. Although the National Comprehensive Cancer Network (NCCN) recommends concurrent chemo-radiotherapy (CCRT) for stage II disease, evidence regarding its efficacy is weak, and this has not been defined as a primary endpoint in phase III trials.

To determine whether or not combined chemotherapy and radiotherapy confers survival benefit to stage II NPC patients, Qui-Yan Chen, M.D., Ph.D., of the Sun Yat-sen University Cancer Center in the People's Republic of China, and colleagues, conducted a phase III trial of patients randomly assigned to receive either radiation therapy (114 patients) or combined chemotherapy and radiation (116 patients).

They also found that after a median follow-up of 60 months, 22.8% of patients in the radiation group had disease progression, compared to 11.2% in the concurrent therapy group. The researchers found that 5-year overall survival, progression-free survival, and distant metastasis-free survival were statistically significantly higher in the concurrent therapy group compared with the group receiving radiation alone.

The authors conclude that based on the results of this trial, which they believe to be the first phase III trial to compare CCRT and RT, the NCCN guidelines are reasonable. They hypothesize that early-stage disease may have a smaller distant tumor bulk, and thus CCRT may be more effective in eradicating distant micro-metastases. Although patients in the combined therapy group experienced more toxic side effects than patients who only received radiotherapy, the regimen was overall well tolerated when the chemotherapy drug dose was reduced.

Chen et al write, "In summary, we think that the optimal choice for early-stage NPC is cisplatin, at a weekly dose of 30 mg/m2, for both an optimal chemotherapy effect to eradicate small distant tumors and to ensure NPC patient compliance."


'/>"/>
Contact: Kristine Crane
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. New study introduces the prospect for concurrent antiangiogenic/antitumorigenic therapy
2. Concurrent chemo and radiation therepy improves long-term survival for inoperable stage III lung cancer
3. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
4. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
5. Scientists identify microRNA as possible cause of chemotherapy resistance
6. Study evaluates costs and benefits of new chemotherapy drugs
7. Older Colon Cancer Patients Less Likely to Get Chemo
8. Are New Chemo Treatments Cost-Effective?
9. BioSphere Medical's HepaSphere Microspheres Safely Deliver Doxorubicin in Liver Cancer Chemoembolization Therapy -- Study Presented at SIR
10. Researchers find new chemotherapy combination shows promise in endometrial cancer
11. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... KS (PRWEB) , ... February ... ... StaffBridge sets a new technology standard in staffing, scheduling, and reporting for ... monitor, and predict activity throughout the entire staffing process. StaffBridge technology improves ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... after receiving cognitive rehabilitation, according to a study released today at the 1st ... cognitive rehabilitation programs are proven to be effective in improving cognitive function in ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ability ... Film Studios. With ProSharpen Color users have total control over sharpening amount, sharpening radius, ... range. With color spectrum tools users can visually see the color range effected with ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston ... options at his office, Antoine Dental Center. Currently, patients can get single dental ... may apply, but patients can learn more about these offers by contacting Antoine ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... business development, education, networking and recognition opportunities as well as advocacy for the ... in Holmdel, NJ on February 23. The Council's Innovation Forecast event highlights ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... STOCKHOLM , Feb 27, 2017 Period October – ... Operating result amounted to SEK -16.4 (-6.4) million ... -0.27 per share (-0.22) before and after dilution Cash flow ... ... amounted to SEK 0.4 (0.4) million Operating result amounted to ...
(Date:2/24/2017)... -- Research and Markets has announced the addition of ... Forecast to 2025" report to their offering. ... The Global Wireless Health Market ... the next decade to reach approximately $330.5 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:2/24/2017)... and Markets has announced the addition of the "Dry eye Drugs ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... following questions: What are the key drugs ... in the Global Dry eye market? What are the ...
Breaking Medicine Technology: